Epsilon aminocaproic acid (EACA) can be used in the treatment of adverse effects caused by :
**Core Concept**
Epsilon aminocaproic acid (EACA) is a synthetic amino acid derivative that acts as a lysine analog and a proteolytic enzyme inhibitor. It is used to inhibit fibrinolysis and prevent excessive bleeding.
**Why the Correct Answer is Right**
EACA works by competitively inhibiting the binding of plasminogen to fibrin, thereby preventing the conversion of plasminogen to plasmin, a key enzyme in the fibrinolytic pathway. This leads to the stabilization of fibrin clots and the prevention of excessive bleeding. EACA is particularly useful in the treatment of bleeding complications associated with fibrinolytic disorders, such as disseminated intravascular coagulation (DIC) and bleeding after surgical procedures.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because EACA is not primarily used to treat thrombotic disorders. While it may have some antithrombotic effects, its primary mechanism of action is to inhibit fibrinolysis.
**Option B:** This option is incorrect because EACA is not a direct vasopressor agent. While it may have some indirect effects on blood pressure, its primary use is to prevent excessive bleeding.
**Option C:** This option is incorrect because EACA is not a direct antiplatelet agent. While it may have some indirect effects on platelet function, its primary use is to inhibit fibrinolysis.
**Clinical Pearl / High-Yield Fact**
EACA is particularly useful in the treatment of bleeding complications associated with fibrinolytic disorders, such as DIC and bleeding after surgical procedures. It is also used to prevent excessive bleeding in patients undergoing surgical procedures that may be at high risk for bleeding.
**Correct Answer:** D.